Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure‐FLT3 Relationship

Sorafenib administered at the approved dose continuously is not tolerated long‐term in patients with acute myeloid leukemia (AML). The purpose of this study was to optimize the dosing regimen by characterizing the sorafenib exposure‐response relationship in patients with AML. A one‐compartment model...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tao, Ivaturi, Vijay, Sabato, Philip, Gobburu, Jogarao V. S., Greer, Jacqueline M., Wright, John J., Smith, B. Douglas, Pratz, Keith W., Rudek, Michelle A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039208/
https://www.ncbi.nlm.nih.gov/pubmed/29702736
http://dx.doi.org/10.1111/cts.12555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039208/
https://www.ncbi.nlm.nih.gov/pubmed/29702736
http://dx.doi.org/10.1111/cts.12555

Ejemplares similares